Skip to main content

William T. Whelan

Mergers & Acquisitions

  • Represented Censa Pharmaceuticals in its option/collaboration/acquisition transaction with Retrophin (NASDAQ: RTRX)
  • Represented Allegro Diagnostics in its merger with Veracyte, Inc. (NASDAQ: VCYT)
  • Represented Ember Corporation in its merger with Silicon Laboratories, Inc. (NASDAQ: SLAB)
  • Represented Pluromed, Inc. in its merger with Sanofi
  • Represented Boston Biomedical, Inc. in its merger with Dainippon Sumitomo Pharma Co., Ltd.
  • Represented Caliper Life Sciences, Inc. (NASDAQ: CALP) in its merger with PerkinElmer, Inc. (NYSE: PKI)
  • Represented Visigen Biotechnologies, Inc. in its merger with Invitrogen Corporation (currently known as Life Technologies, Inc. (NASDAQ: LIFE))
  • Represented V.I. Technologies, Inc. (NASDAQ: VITX) in its merger with Panacos Pharmaceuticals, Inc. (NASDAQ: PANC)
  • Represented EPIX Pharmaceuticals, Inc. (NASDAQ: EPIX) in its merger with Predix Pharmaceuticals, Inc.
  • Represented Caliper Life Sciences, Inc. (NASDAQ: CALP) in its merger with Xenogen Corporation (NASDAQ: XGEN)
  • Represented Focus Technologies Holding Company in its acquisition by Quest Diagnostics Incorporated (NYSE: DGX)
  • Represented the MacGregror Group, Inc. in its acquisition by Investment Technology Group, Inc. (NYSE: ITG)

Public & Private Offerings for Public Companies

  • Represented Quanterix Corporation (NASDAQ: QTRX) in its initial public offering
  • Represented NuCana (NASDAQ: NCNA) in its initial public offering
  • Represented Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) in its initial public offering
  • Represented BG Medicine, Inc. (Nasdaq: BGMD) in its initial public offering
  • Represented Coley Pharmaceutical Group, Inc. (NASDAQ: COLY) in its initial public offering
  • Represented Panacos Pharmaceuticals, Inc. (NASDAQ: PANC) in a follow-on public offering
  • Represented EPIX Pharmaceuticals, Inc. (NASDAQ: EPIX) in its initial public offering and a Rule 144A offering of convertible notes
  • Represented Predix Pharmaceuticals, Inc. in its initial public offering

Venture Capital Financings

  • Represented Quanterix Corporation in its Series D Preferred Stock financing
  • Represented Vedanta Biosciences in its Series B Preferred Stock financing
  • Represented ERX Pharmacueticals, Inc. in its initial institutional preferred stock financing
  • Represented Caribou Biosciences, Inc. in its Series B Preferred Stock financing
  • Represented Biogen Inc. in its preferred stock investment in Yumanity, Inc.
  • Represented Anchor Therapeutics, Inc. in various preferred stock and debt financings
  • Represented Pulmatrix, Inc. in various preferred stock and debt financings
  • Represented Luminus Devices, Inc. in various preferred stock and debt financings
Case Study
Mintz steered precision health company Quanterix Corporation through a $73.7 million initial public offering (IPO). The firm’s Securities & Capital Markets Practice advised Quanterix on the Securities and Exchange Commission review process as well as pricing and timing of the offering.